BCL6 represses NFkappaB activity in diffuse large B-cell lymphomas - PubMed (original) (raw)
. 2008 Mar;214(4):498-507.
doi: 10.1002/path.2279.
Affiliations
- PMID: 18189332
- DOI: 10.1002/path.2279
BCL6 represses NFkappaB activity in diffuse large B-cell lymphomas
A Perez-Rosado et al. J Pathol. 2008 Mar.
Abstract
BCL6 is a transcriptional repressor whose deregulated expression plays a key role in diffuse large B-cell lymphomas (DLBCLs). BCL6 expression characterizes one of the two main subtypes (GC type) of DLBCL, while the other (ABC type) is recognized by increased NFkappaB activation. The mechanistic basis of this distinction remains unclear and the BCL6 targets have been only partially explored. Here we describe how NFkappaB activity is increased after BCL6 silencing by shRNA in DLBCL cells, leading us to propose that BCL6 represses NFkappaB activity. We also demonstrate that this repression is brought about by a mechanism involving protein-protein interaction between BCL6 and NFkappaB members, both in vitro and in vivo. Analysis of a series of DLBCLs shows a negative correlation between the expression of NFkappaB target genes and BCL6. This combined approach using silenced cells and a series of human DLBCL samples leads us to a better understanding of the role of BCL6 as an NFkappaB regulator in B-cells.
Similar articles
- Tissue microarray is inappropriate for analysis of BCL6 expression in diffuse large B-cell lymphoma.
Linderoth J, Ehinger M, Akerman M, Cavallin-Ståhl E, Enblad G, Erlanson M, Jerkeman M. Linderoth J, et al. Eur J Haematol. 2007 Aug;79(2):146-9. doi: 10.1111/j.1600-0609.2007.00892.x. Eur J Haematol. 2007. PMID: 17635238 - STAT5 represses BCL6 expression by binding to a regulatory region frequently mutated in lymphomas.
Walker SR, Nelson EA, Frank DA. Walker SR, et al. Oncogene. 2007 Jan 11;26(2):224-33. doi: 10.1038/sj.onc.1209775. Epub 2006 Jul 3. Oncogene. 2007. PMID: 16819511 - BCL6: master regulator of the germinal center reaction and key oncogene in B cell lymphomagenesis.
Basso K, Dalla-Favera R. Basso K, et al. Adv Immunol. 2010;105:193-210. doi: 10.1016/S0065-2776(10)05007-8. Adv Immunol. 2010. PMID: 20510734 Review. - Targeted somatic mutation of the BCL6 proto-oncogene and its impact on lymphomagenesis.
Jardin F, Sahota SS. Jardin F, et al. Hematology. 2005 Apr;10(2):115-29. doi: 10.1080/10245330400026105. Hematology. 2005. PMID: 16019457 Review.
Cited by
- MicroRNA-155 promotes atherosclerosis by repressing Bcl6 in macrophages.
Nazari-Jahantigh M, Wei Y, Noels H, Akhtar S, Zhou Z, Koenen RR, Heyll K, Gremse F, Kiessling F, Grommes J, Weber C, Schober A. Nazari-Jahantigh M, et al. J Clin Invest. 2012 Nov;122(11):4190-202. doi: 10.1172/JCI61716. Epub 2012 Oct 8. J Clin Invest. 2012. PMID: 23041630 Free PMC article. - NF-kappaB pathways in the immune system: control of the germinal center reaction.
Goetz CA, Baldwin AS. Goetz CA, et al. Immunol Res. 2008;41(3):233-47. doi: 10.1007/s12026-008-8033-1. Immunol Res. 2008. PMID: 18670738 Review. - B-cell lymphoma 6 and the molecular pathogenesis of diffuse large B-cell lymphoma.
Ci W, Polo JM, Melnick A. Ci W, et al. Curr Opin Hematol. 2008 Jul;15(4):381-90. doi: 10.1097/MOH.0b013e328302c7df. Curr Opin Hematol. 2008. PMID: 18536578 Free PMC article. Review. - Male-dominant activation of rat renal organic anion transporter 1 (Oat1) and 3 (Oat3) expression by transcription factor BCL6.
Wegner W, Burckhardt BC, Burckhardt G, Henjakovic M. Wegner W, et al. PLoS One. 2012;7(4):e35556. doi: 10.1371/journal.pone.0035556. Epub 2012 Apr 18. PLoS One. 2012. PMID: 22530049 Free PMC article. - Rewiring cancer drivers to activate apoptosis.
Gourisankar S, Krokhotin A, Ji W, Liu X, Chang CY, Kim SH, Li Z, Wenderski W, Simanauskaite JM, Yang H, Vogel H, Zhang T, Green MR, Gray NS, Crabtree GR. Gourisankar S, et al. Nature. 2023 Aug;620(7973):417-425. doi: 10.1038/s41586-023-06348-2. Epub 2023 Jul 26. Nature. 2023. PMID: 37495688 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous